SciSparc Ltd. (SPRC)
NASDAQ: SPRC · Real-Time Price · USD
1.340
+0.010 (0.75%)
At close: Oct 21, 2026, 4:00 PM EDT
1.270
-0.070 (-5.22%)
Pre-market: Oct 22, 2026, 5:04 AM EDT
SciSparc Revenue
SciSparc had revenue of $142.00K in the quarter ending June 30, 2026, a decrease of -38.39%. This brings the company's total for the last twelve months to $679.00K, down -61.57% year-over-year. In the year 2025, SciSparc had annual revenue of $856.00K, down -34.46%. That makes SciSparc the 44,147th largest company in the world by revenue and 6,232nd in the United States.
Revenue (ttm)
$679.00K
Revenue Growth
-61.57%
P/S Ratio
1.15
Revenue / Employee
$226,333
Employees
3
Market Cap
778.50K
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 856.00K | -450.00K | -34.46% |
| Dec 31, 2024 | 1.31M | -1.57M | -54.64% |
| Dec 31, 2023 | 2.88M | 1.53M | 113.73% |
| Dec 31, 2022 | 1.35M | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Jaguar Health | 27.82M |
| Curis | 4.31M |
| Decoy Therapeutics | 227.63K |
| Endovia Health Sciences | 32.09K |
| Virax Biolabs Group | 12.42K |
| Valion Bio | -86.00K |
SPRC News
- 2 days ago - SciSparc Shifts Focus to Agentic AI, Targeting Cybersecurity and Finance Applications - GlobeNewsWire
- 6 days ago - SciSparc shifts focus toward Agentic AI-powered technologies - TheFly
- 6 days ago - SciSparc Announces Transformation into Agentic AI-Powered Technologies, Including Cybersecurity and Finance Technologies - GlobeNewsWire
- 14 days ago - SciSparc: Subsidiary NeuroThera Labs' CliniQuantum Reports Successful Quantum-Enabled Analysis of Billions of Gene Combinations Using Real-World Clinical Data on an S&P 500 Company's Quantum Architecture - GlobeNewsWire
- 4 weeks ago - SciSparc expands U.S. IP portfolio in collaboration with Clearmind Medicine - TheFly
- 4 weeks ago - SciSparc: Subsidiary NeuroThera Highlights Enhancement of U.S. Patent Portfolio Through Collaboration with Clearmind Covering LSD, Ketamine and Ibogaine Combinations - GlobeNewsWire
- 7 weeks ago - SciSparc Subsidiary NeuroThera Labs Pursues FDA Orphan Drug Designation for Adult Tourette Syndrome Drug; Engages Government and Public Affairs Firm RK Strategies - TheNewswire
- 7 weeks ago - SciSparc: Subsidiary NeuroThera Labs Pursues FDA Orphan Drug Designation for Adult Tourette Syndrome Drug; Engages Government and Public Affairs Firm RK Strategies - TheNewswire